February 25, 2025 07:00 AM EST
R&D

Al­ny­lam eyes big­ger dis­eases in more tis­sue types at ‘in­flec­tion point’ for siR­NA

Ryan Cross

Senior Science Correspondent

Al­ny­lam may be gear­ing up for its biggest com­mer­cial launch yet in its near­ly 23-year his­to­ry, but the com­pa­ny’s top sci­en­tists be­lieve they are just …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Where the mon­ey is: The top 100 ven­ture in­vestors in biotech

Lil­ly pays $10M up­front for Organo­vo’s FXR ag­o­nist pro­gram

Re­pare to lay off 75% of staff; Cas­tle Creek inks $75M roy­al­ty deal

Eli Lil­ly ex­pands Zep­bound sin­gle-dose vial op­tions at low­er price

Brid­Gene nets an­oth­er Take­da deal amid plans to raise more fund­ing and go pub­lic

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times